You are definitely not an Abbvie employee or you are on another planet. The FDA has no concerns or jurisdiction over pricing of drugs. They also cannot prevent a drug from being launched that has solid efficacy and safety data. Harvoni has no clinical advantage over 3D. I would also say that the whole one pill QD is overblown. Firstly, the HCV population is generally highly motivated and a one pill regimen will impact adherence very little, if at all. Second, Docs will not prescribe the meds to patients who are in the midst of drug abuse or have other psychosocial issues that would impact adherence. Payors will also not approve the meds for those who are using drugs (all payors are requiring negative drug screens and at least 3 months clean from drugs).
3D has numerous clinical advantages over Harvoni: better in GT 1b (100% SVR), better cirrhotic data (larger numbers and more reliable data), lower failure rate in treatment experienced patients (Sapphire-2 vs. Ion-2), Harvoni cannot be used in pts with GFRs < 30, no Omeprazole > 20mg with Harvoni (at least 40% of patients in GI offices are on 40mg), solid co-infection and post transplant data.